Actively Recruiting
The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks
Led by General Hospital of Shenyang Military Region · Updated on 2025-12-08
2800
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Atherosclerotic cardiovascular disease (ASCVD) is a group of disorders sharing atherosclerosis as a common pathological basis, primarily affecting the heart, brain, kidneys, and other peripheral arteries, leading to clinical syndromes characterized mainly by arterial ischemia. It has become the group of diseases with the highest morbidity and mortality rates worldwide. Patients with very high-risk ASCVD face an even greater risk of recurrence. Previous studies have discovered that remote ischemic conditioning (RIC) has protective effects on major organs such as the heart, brain, and kidneys. Given the cardiorenal and cerebrovascular protective effects of RIC, the invesitgators believe that long-term remote ischemic conditioning is a promising approach to preventing the recurrence of ASCVD events. Based on this hypothesis, the investigators have designed a prospective, multicenter cohort study with blinded outcome assessment to investigate the protective effects of long-term remote ischemic conditioning in very high-risk ASCVD populations.
CONDITIONS
Official Title
The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 40 years
- Two or more prior major ASCVD events; OR one documented major ASCVD event with two or more specified risk factors
- Signed informed consent
- Major ASCVD events include acute coronary syndrome within the past year, history of myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease
- Risk factors include age 65 or older, heterozygous familial hypercholesterolemia, prior coronary artery bypass surgery or percutaneous coronary intervention, diabetes mellitus, hypertension, chronic kidney disease, current smoking, high LDL cholesterol despite treatment, and history of congestive heart failure
You will not qualify if you...
- Severe neurological deficit with modified Rankin Scale score 3 or higher
- Uncontrolled severe hypertension (systolic > 180 mmHg or diastolic > 110 mmHg despite medication)
- Subclavian artery stenosis 50% or more or subclavian steal syndrome
- Severe blood disorders or significant clotting problems
- Contraindications to remote ischemic conditioning such as severe soft tissue injury, fracture, or vascular injury in upper limbs, or peripheral vascular disease in distal upper limbs
- Severe other illnesses with life expectancy under 1 year
- Participation in another clinical trial within the past 3 months or ongoing trial participation
- Any other conditions judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here